Abstract: Provided are conducting polymer nanofibers, methods of making conducting polymer nanofibers, and uses thereof. The conducting polymer nanofibers can be formed by, for example, electrospinning, force spinning, and centrifugal spinning using a spinning dope. The conducting polymer nanofibers can be used in devices, such as a radiation detecting device.

Abstract: Electro-osmosis is used to create droplets in order to easily, carefully, and quickly pick-and-place millions of objects (ranging in size from millimeters to nanometers) individually or in parallel. Droplets are formed within channels that are individually controlled in order to achieve a predetermined configuration of the selected objects.

Abstract: The androgen receptor (AR) is the key driver of prostate differentiation and prostate cancer (PC) progression, and androgen ablation is the cornerstone of advanced PC treatment. Prostate-specific membrane antigen (PSMA) represents another target of interest in PC. Previous publications have reported inconsistent associations between androgen levels and PSMA expression. Using a panel of prototypical human PC cell lines, this relationship is clarified. PSMA is a biomarker that distinguishes AR-positive/PSMA-positive adenocarcinomas from AR-negative variants. PSMA is a cell surface barometer of androgen activity that can be readily identified by immunohistochemistry and/or in vivo imaging. Given that anti-androgen therapy is likely to remain a cornerstone of PC treatment, the associated up-regulation of PSMA, as well as its other characteristics, makes it a compelling target opportunity in PC.

Abstract: A nanodevice includes a substrate that has an elongated channel with a plurality of nanoscale critical dimensions arranged as a stepped gradient across a width of the elongated channel.

Abstract: Prostate cancer (PC) is an entity that encompasses different types of tumors, including adenocarcinomas and non-adenocarcinomas. Adenocarcinomas and non-adenocarcinomas respond to, and therefore should be treated, with different treatments. Even within the adenocarcinomas, the lethality of tumors is highly variable, from low risk/indolent/non-life threatening to high risk/lethal. The inability to accurately predict the behavior of a particular cancer makes treatment decisions difficult and highly inexact. Elevated expression of prostate specific membrane antigen (PSMA) expression is a molecular hallmark of lethal prostate adenocarcinoma. Assessment of PSMA expression levels to predict the behavior of a particular cancer will be useful in the diagnosis and treatment of PC.

Abstract: A nanoparticle organic hybrid material (NOHM) containing an organic polymeric corona having a molecular weight in a range of 100-50,000 g/mol, wherein the organic polymeric corona is covalently attached to an inorganic nanoparticle core, wherein the NOHM exhibits liquid-like properties so that the NOHM moves freely and flows in a manner so that when the NOHM is in a container, the NOHM takes the shape of the container, and wherein the NOHM has a volume fraction (fc) of the inorganic particle ranging from about 0.05 to 0.75, methods of making the NOHMs, and compositions containing the NOHMs.

Abstract: Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the Leptospira OMPs can be used to create, manufacture or improve vaccines. Vaccines, including but not limited to DNA vaccines, recombinant vaccines, and T-cell epitope vaccines based on the foregoing OMPs are also provided. Methods for producing such vaccines are also provided. Also provided are methods for using Leptospira OMP genes, proteins and antibodies for therapeutic treatment and serological diagnosis techniques.

Abstract: A mesoporous silica particle having 10 mole % to 65 mole % amine groups present in the silica of the particle and on the silica surface of the particle. The particle has Pm 3n symmetry and a size of 25 nm to 500 nm. Methods of making such particles from the low temperature reaction of silane precursor and amino silane precursors is provided. The particle can be used in applications such as imaging, drug delivery, catalysis, and CO2 sequestration.

Abstract: The present invention relates to a method for quantifying elemental sulfur levels in a test sample. This method involves the steps of: (i) providing a test sample having an unknown amount of elemental sulfur; (ii) converting the elemental sulfur contained in the test sample into volatilized hydrogen sulfide using benign reagents and without prior need to purify the elemental sulfur in the test sample by extraction or other purification processes; and (iii) determining the amount of volatilized hydrogen sulfide from the test sample in order to quantify the amount of elemental sulfur contained in the test sample. The present invention also relates to kits, systems, and assays for quantifying elemental sulfur levels in a test sample.

Abstract: The present invention relates to nano structures of metal oxides having a nanostructured shell (or wall), and an internal space or void. Nanostructures may be nanoparticles, nanorod/belts/arrays, nanotubes, nanodisks, nanoboxes, hollow nanospheres, and mesoporous structures, among other nanostructures. The nanostructures are composed of polycrystalline metal, oxides such as SnO2. The nanostructures may have concentric walls which surround the internal space of cavity. There may be two or more concentric shells or walls. The internal space may contain a core such ferric oxides or other materials which have functional properties. The invention also provides for a novel, inexpensive, high-yield method for mass production of hollow metal oxide nanostructures. The method may be template free or contain a template such as silica. The nanostructures prepared by the methods of the invention provide for improved cycling performance when tested using rechargeable lithium-ion batteries.

Abstract: The present invention is directed to a synthetic nucleic acid scaffold comprising one or more subunits, each subunit comprising two or more different protein-binding sequences coupled together. The present invention further relates to systems and methods for assembling a synthetic biological pathway and producing a biological pathway product or a precursor product using the synthetic nucleic acid scaffold.

Abstract: Clock synchronization error is corrected or minimized by fitting a parabolic f(T) function to the crystal's data, and compensating for sampling period drift in an Analog to Digital Converter (ADC) at various temperatures.

Abstract: The present invention relates to a method of treating hyperalgesia in a subject, which involves administering to a subject an amount of a TRPV1 agonist compound that selectively inhibits hyperactive nociceptive neurons. The present invention also relates to a method of selectively inhibiting hyperactive nociceptive neurons. Also disclosed is a method for reducing the electrical activity of hypersensitive neurons sensitized to TRPV1. The present invention also relates to a method for identifying candidate compounds that selectively inhibit hyperactive nociceptive neurons. Also disclosed is a pharmaceutical composition.

Abstract: A device comprising a single closed loop of elastic filament configurable between (i) a first configuration for movement along a blood vessel; and (ii) a second configuration for lodging within a blood vessel, the second configuration providing a single flow-restricting face sized and configured to cover the mouth of the aneurysm and obstruct blood flow to the aneurysm while permitting substantially normal blood flow through the blood vessel, with the degree of obstruction at the mouth of the aneurysm being such that the aneurysm thromboses when the face is positioned over the aneurysm, the flow-restricting face comprising a plurality of lengths of the closed loop of filament disposed in close proximity to one another in a switchback configuration, and at least one leg for holding the flow-restricting face adjacent the mouth of the aneurysm, the leg configured so as to maintain substantially normal blood flow through the blood vessel.

Abstract: The present invention relates to a method and kit for identifying a translation initiation site on an mRNA. The method involves contacting a first mRNA with a first translation inhibitor to preferentially stabilize one or more initiation ribosomes at translation initiation sites on the first mRNA. A second mRNA is contacted with a second translation inhibitor different from the first translation inhibitor to stabilize one or more initiation ribosomes and one or more elongation ribosomes on the second mRNA. The location of ribosomes stabilized on the first mRNA is compared to the location of ribosomes stabilized on the second mRNA.

Abstract: The present invention provides novel bimetallic complexes and methods of using the same in the isoselective polymerization of epoxides. The invention also provides methods of kinetic resolution of epoxides. The invention further provides polyethers with high enantiomeric excess that are useful in applications ranging from consumer goods to materials.